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ABSTRACT
At highly elevated temperatures, many biological reactions can proceed spontaneously from
the ground state to the transition state. However, due to the long half-life of these reactions,
catalysts are required to catalyze these reactions at modern day temperatures by lowering the
activation energy. Wolfenden et al. has previously shown that catalysts enhance the rate of the
reaction by reducing the enthalpy of activation. Therefore, the activation energies have been
determined for three aminoglycoside modifying enzymes, APH(3’)-IIIa, AAC(3)-IIIb, and
AAC(3)-VIa, to determine whether these three enzymes distinguish between the two classes
of aminoglycoside antibiotics by reducing the enthalpy of activation during catalysis.
Aminoglycosides are broad-spectrum antibiotics active against Gram-positive and Gramnegative organisms. These antibiotics contain a 2-deoxystreptamine ring and are classified
into two classes: the 4,6-di-substituted kanamycin-like aminoglycosides and the 4,5-disubstituted neomycin-like aminoglycosides. Since their discovery in the 1940s, bacteria have
shown a high level of resistance to these antimicrobial agents mainly due to the emergence of
aminoglycoside modifying enzymes (AGMEs). AGMEs are classified into three main
families based on the type of modification reaction: (a) O-Nucleotidyltransferases (ANT)
catalyze the adenylation reaction of hydroxyl groups in the presence of ATP; (b) OPhosphotransferases (APH) phosphorylate hydroxyl groups in the presence of ATP; (c) and
N-Acetyltransferases (AAC) which acetylate an amino group on the 2-deoxystreptamine ring
or aminohexose sugar rings in the presence of acetyl coenzyme A as the acetyl donor.
APH(3’)-IIIa and AAC(3)-IIIb are two very promiscuous AGMEs while AAC(3)-VIa has a
limited substrate profile. In general, there were no observed trends in the activation energies
that distinguished between the two classes of aminoglycoside antibiotics for APH(3’)-IIIa and
AAC(3)-IIIb. When studying the activation energies for a more hydrophobic aminoglycoside,
gentamicin C1 [C1] and C2 [C2], AAC(3)-IIIb appeared to favor the more methylated
gentamicin component, gentamicin C1 [C1], whereas AAC(3)-VIa was shown to have a lower
activation energy for gentamicin C2 [C2].
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CHAPTER I: INTRODUCTION
A. Temperature-Dependent Rate Enhancements Produced by a Catalyst
I. Chemical Reaction Pathway
Spontaneous chemical reactions proceed from the initial collision of molecules at the
ground state to the transition state, the highest energy state, and proceed to product formation.
Shown in figure 1, an uncatalyzed reaction (red line) must overcome a substantially high
activation energy (kinetic barrier) before reaching the transition state, thereby having an
overall unfavorable reaction pathway. Due to an extremely high kinetic barrier, many
biological reactions require a catalyst to reduce the activation energy (green line). Without
the presence of catalysts, many necessary biological reactions will spontaneously occur but
not within a relevant time frame due to a high half-life for the uncatalyzed reaction. Such
reactions have been shown with peptide hydrolysis, which has a half-life of ~500 years or αglucosidase, which has a half-life of 1014 years1,2,3,4.

Figure 1: Free energy diagram for enzyme catalysis, showing the activation energy to the
transition state required for a nonenzymatic reaction (red) and in the presence of a catalyst
(green)2.
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II. Rate Enhancements produced by Catalysts
Two generalizations about rate enhancements produced by catalysts have been
summarized by Wolfenden et al.: (a) the rates of chemical reactions increase as temperature
increases; (b) the rate of product formation from the transition state doubles as temperature
increases by 10°C. For these generalizations to hold true, catalyzed and uncatalyzed reactions
would exhibit similar heats of activation, mainly associated with a more favorable entropy of
activation. Therefore, Wolfenden et al. conducted a series of studies with biological catalysts
to examine the role of enthalpy and entropy of activation in enzyme catalysis1. When the
enthalpy and entropy of activation values were plotted for numerous spontaneous biological
reactions, the spontaneous reactions were observed to have a significant change in the
enthalpy of activation while the entropy of activation remained fairly constant. These
observations suggested that primordial enzymes enhanced the rate of the reaction by lowering
the enthalpy of activation thereby improving the effectiveness of the catalyst. Furthermore, it
has been proposed that the rate enhancement corresponded with an increase in affinity to the
transition state and that the effectiveness of primordial enzymes improved as the earth cooled.
When the earth first formed ~4.6 million years ago, biological reactions may have proceeded
spontaneously due to extremely high temperatures. As the earth cooled to modern day
temperatures, enzymes required for biological reactions may have increased their efficiencies
to catalyze the reactions by reducing the enthalpy of activation. One example that supports
this hypothesis is the temperature dependence of glycoside hydrolysis, where the rate
enhancement was achieved by reducing the enthalpy of activation for the catalyzed reaction.
In the presence of α-glucosidase, the rate enhancement for the catalyzed reaction was much
faster at ordinary temperatures compared to the spontaneous reaction. Illustrated in figure 2,
the rate enhancement for the catalyzed reaction improved as temperatures decreased.
Intuitively, the increase in rate enhancement at lower temperatures would be consistent with
the cooling of the earth to present day temperatures1,2,3. An exception to the enzymes that
reduced the enthalpy of activation was peptidyl transferase, an enzyme that is specific to the
ribosome for peptide bond formation in protein synthesis1,2. For this catalyst, the rate
enhancement was achieved solely by a favorable entropy of activation rather than a favorable
enthalpy of activation. This phenomenon appeared to be consistent with substrate specific
2

enzymes whereas the rate enhancement produced by catalysts was more associated with the
reduction of activation enthalpy. Overall, catalysis appears to be driven by the enthalpy of
activation, which may provide further support to the thermodynamic behavior of enzymes that
bind tightly to the active site by inducing conformational changes and formation of new
electrostatic interactions and hydrogen bonds in the transition state1,2,3,4.

Figure 2: The effect of temperature on the rate enhancement for the catalyzed and
uncatalyzed reaction for glucoside hydrolysis. The rate enhancement by α-glucosidase was
achieved by reducing the enthalpy of activation and was more pronounced at lower
temperatures (white wedge). The bold lines indicate the temperature range at which the
reactions were measured1,2.
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B. Aminoglycoside Antibiotics

I. Discovery of Aminoglycosides and Chemical Structure
Aminoglycoside antibiotics are broad-spectrum antibacterial agents used mainly to
treat bacterial infections caused by Gram-positive and Gram-negative bacteria. They have also
been shown to be effective against amaeboid or protozoal infections and are inhibitors of
HIV-1 production. Aminoglycosides are a large family of hydrophilic, highly polar,
polycationic molecules comprised of multiple amino sugar rings possessing several amino and
hydroxy functional groups. Many of these compounds are natural products produced by
bacteria. The antibiotics synthesized by Streptomycetes are denoted by –mycin whereas the
antibiotics synthesized by Micromonospora are denoted by –micin. Streptomycin was
isolated from Streptomyces griseus in 1944 by Selman Waksman and was the first
aminoglycoside to be used in clinical treatments against tuberculosis. Since the discovery of
this antibiotic, aminoglycosides have been vital broad-spectrum antibacterial agents for
treatments against numerous infections and are critically important to present day drug
discovery5,6.
Aminoglycosides are classified into two main structural classes, those that contain a 2deoxyamine ring and those that do not. Further classification of aminoglycoside antibiotics
containing the 2-deoxyamine ring can be subdivided into the kanamycin and neomycin groups
based on their substitution patterns on the 2-deoxyamine ring. The kanamycin-like class of
aminoglycosides are di-substituted at the 4,6-position on the 2-deoxystreptamine ring, while
the neomycin-like class of aminoglycosides are di-substituted at the 4,5-position on the 2deoxystreptoamine ring (figure 3). For the neomycin class, the number of amino modified
sugar rings range from two to six. The conventional numbering for each amino sugar ring is
determined at the 6-aminohexose ring linked to position 4 on the 2-deoxyamine ring, denoted
as prime (‘), whereas the hexose or pentose ring linked to position 5 or 6 on the 2-deoxyamine
ring is denoted as double prime (“)5,6.

4

Figure 3: Aminoglycoside anitbiotics are classified by structural differences: the kanamycinlike aminoglycosides are disubstituted at the 4,6-position on the 2-deoxystreptamine ring and
are composed of 3 modified amino sugar rings (left), while the neomycin-like
aminoglycosides are disubstituted at the 4,5-position on the 2-deoxystreptamine ring and
range from 2 to 6 modified amino sugar rings (right).

II. Mode of Action
Aminoglycoside antibiotics have a high affinity for prokaryotic ribosomes by binding
to the tRNA binding region (A-site) of the 16S rRNA of the 30S ribosomal subunit. The
uptake of aminoglycosides within the cell is a multiphase process divided into two energydependent phases, EDP-I and EDP-II. Aminoglycosides first gain entry into the cell by an
energy independent, drug-induced, disruption of Mg2+ bridges between lipopolysaccharides in
Gram-negative bacteria or by passing through the cell wall in Gram-positive bacteria. The
transport of aminoglycosides across the cell membrane is an energy-dependent process (EDPI) by electron transport. Once in the cytosol, the aminoglycoside antibiotics rapidly and
reversibly bind to the 30S ribosomal subunit in an energy-dependent manner (EDP-II). The
binding of aminoglycosides to the 30S subunit does not appear to prevent the formation of the
ribosomal complex; rather it impairs the proofreading process and translational accuracy
resulting in misfolded, non-functional proteins. These proteins can interact with the cell
membrane causing a loss in membrane integrity and increase membrane permeability for an
influx of aminoglycoside antibiotic to saturate all of the ribosomes in an irreversible manner,
resulting in cell death6,7,8.
5

The degree of antibiotic activity has been shown to be dependent upon structural
characteristics. Previous studies have shown that the hydroxyl groups have little effect on
antibiotic activity compared to the amino groups. The number of amino groups and positions
at which they are located play a significant role in activity shown in decreasing order of 2’, 6’diamino > 6’-amino > 2’ amino > absence of amine9,10.

C. Aminoglycoside Modifying Enzymes

I. Nomenclature and Mechanism of Modification
Since the discovery of aminoglycoside antibiotics, bacterial resistance has emerged
mainly due to the presence of aminoglycoside-modifying enzymes. Once modified,
aminoglycosides have a low binding affinity for the 30S ribosomal subunit allowing the
bacteria to survive in the presence of the drug. To date, there are over 50 different modifying
enzymes classified into three main families based on the type of functional group transferred
to the aminoglycoside structure and inactivating the antibiotic’s activity. The three groups are:
(a) O-Nucleotidyltransferases (ANT) which utilize ATP as a second substrate to catalyze an
adenylation reaction at the hydroxyl groups; (b) O-Phosphotransferases (APH) which catalyze
the ATP-dependent phosphorylation of hydroxyl groups; and (c) N-Acetyltransferases (AAC)
which acetylate an amino group on the 2-deoxystreptamine ring or aminohexose sugar rings in
the presence of acetyl coenzyme A as the acetyl donor. Each family of aminoglycoside
modifying enzymes contains numerous genes differing in substrate regiospecificity and
promiscuity (figure 4)6,11,12.
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Figure 4: Site of modification for kanamycin B by aminoglycoside modifying enzymes.

D. Introduction to Aminoglycoside -3’-Phosphotransferase-IIIa
The APH family of enzymes is one of the best studied of the aminoglycoside
modifying enzymes. This family shows sequence homology at the carboxy end of the protein
and contains four subfamilies based on their site of modification: -2”, -3’, 3”, -6, -4. Of the
APHs, the APH(3’) subfamily has at least seven different genes (I-VII) that have been
identified. APH(3’)-IIIa is in particular interest due to its broad substrate profile capable of
modifying both classes of aminoglycosides and at the 3’- and 5”-OH groups: kanamycin A,
kanamycin B, neomycin B, paromomycin, ribostamycin, lividomycin, butirosin, amikacin,
and isepamicin11,12.

I. Structure of APH(3’)-IIIa
APH(3’)-IIIa is a 31kDa enzyme produced by Escherichia coli and Staphylococcus
aureus, both Gram-positive organisms. The gene encoding for APH(3’)-IIIa was cloned from
plasmid pJH1, a 72.6kb R plasmid isolated from a clinical isolate. This enzyme is purified as
a monomer in the presence of dithiothreitol (DTT) and can dimerize without the presence of a
reducing agent. Head to tail covalent bonds connected by two disulfide bonds between Cys19
7

and Cys156 links the homodimer. The dimer contains two active sites, both equally capable
of phosphorylating aminoglycosides13,14. Each monomer consists of two lobes containing five
anti-parallel β-sheets and two α-helices on the N-terminus and six α-helices and four β-strands
on the C-terminus (figure 5). APH(3’)-IIIa resembles traditional protein kinases by utilizing
the transfer of the γ-phosphate of ATP to modify aminoglycosides15. The nucleotide binding
pocket is formed by a cleft between the N- and C-termini and contains six conserved residues
across the APH(3’) family of enzymes: Ser27, Lys44, Glu60, Asp190, Asn195, and Asp208.
Ser27 and Lys44 interact with the γ-phosphate of ATP and increase binding affinity. Asp190
plays a critical for binding of the aminoglycoside while Asn195 and Asp208 stabilize the
Mg2+ ions in the transition state to initiate the release of ADP during the rate-limiting
step15,16,17,18,19,20,21. The aminoglycoside-binding site is lined with acidic, highly negatively
charged residues, which increase the affinity for positively charged aminoglycosides.
Mutagenesis studies confirmed the critical role of Asp190, which is suggested to be the
general base and forms hydrogen bonds with the 3’-OH group on aminoglycosides, the
primary site of modification (figure 6)20,21,22.

Figure 5: Cartoon representation of the structure of APH(3’)-IIIa in complex with ADP
(yellow), Mg2+ (green) and kanamycin A (blue) (PDB: 1L8T)22. The structural representation
of APH(3’)-IIIa was created using YASARI software.
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Figure 6: A cartoon representation of the active site for APH(3’)-IIIa (PDB: 1L8T) in
complex with ADP (red), Mg2+(green), and kanamycin A (orange). The residues participating
in binding are shown in color coded manner: the nucleotide binding region (blue),
triphosphate binding pocket (yellow), specificity pocket (purple) and aminoglycoside catalytic
binding site (cyan) are highlighted20. The representation of the active site for APH(3’)-IIIa
was created in YASARI software.

II. Protein Dynamics in Solution
The dynamic behavior of APH(3’)-IIIa has been studied for the apo-enzyme, binary
complex with aminoglycoside, and ternary complex with the nucleotide and aminoglycoside.
For the apo-enzyme, the Heteronuclear Single Quantum Correlation (HSQC) NMR spectrum
contained a majority of resonances overlapping between ~7.5ppm and 8.8ppm in the H1
dimension. Although these spectra are similar to those of denatured or partially unfolded
proteins, secondary structure does form in the APH (3’)-IIIa apoenzyme but most likely
contains weaker hydrophobic interactions and hydrogen bonds. Therefore, in the absence of
ligand, APH(3’)-IIIa was suggested to be highly flexible and dynamic, capable of sampling
9

several conformational states exhibited by the broadened, overlapping amide resonances
(figure 7A)23.
In the binary complex with only the antibiotic, APH(3’)-IIIa – aminoglycoside, the
HSQC spectrum undergoes a drastic change in proton chemical shifts between 6 ppm and
11ppm for amide resonances. The shift in resonances indicates that APH(3’)-IIIa adopts a
well-defined structure upon aminoglycoside binding. In the ternary complex, ~30 cross-peaks
exhibited line broadening associated with amino acids located near the nucleotide binding site
that were present in the binary complex. In other words, the APH-nucleotide-aminoglycoside
complex gains more flexibility as compared to the binary enzyme–aminoglycoside complex. ,
. The solvent accessibility however increased by >20 unbroadened residues (figure 7C)23.
This is consistent with the fact that the binary enzyme–nucleotide complex is as flexible as the
apo-enzyme.
In both the APH-neomycin and APH-kanamycin A ternary complexes, the Lys44 peak
was absent in the HSQC spectra. Lys44 is situated within the nucleotide-binding site and was
suggested to make direct contact with this ligand. Val57 and Glu60 also showed increased HD exchange in the neomycin ternary complex but exhibited line broadening in the kanamycin
A ternary complex. All of these residues are located within an α-helix and participate in
hydrogen bonding with the five stranded, antiparallel β-sheet at the nucleotide-binding
cleft17,22. In particular, Glu60 forms electrostatic interactions to stabilize Lys44, allowing
Lys44 to be more stable when making contacts with the nucleotide. Furthermore, it was
proposed that ATP binding slightly destabilizes APH-(3’)-IIIa by weakening or breaking
hydrogen bonds formed between the α-helix and β-sheet at the nucleotide-binding interface23.
Further evidence for the destabilization of the β-sheet was shown in the binary complex in the
presence and absence of β-γ-methylene 5’-triphosphate (AMPPCP) and MgCl2, an MgATP
analogue. In the absence of Mg-AMPPCP, slow H-D exchange (strong protection of solvent)
was exhibited compared to the fast exchange observed when Mg-AMPPCP was present. This
was observed in both kanamycin A- and neomycin B ternary complexes, with the exception
that the neomycin B ternary complex has less broadened residues, suggesting that neomycin B
induces greater protein stability than kanamycin A23.
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Figure 7: HSQC NMR spectrum for APH(3’)-IIIa in apo-form (A), in complex with MgATP
(B), in complex with tobramycin (C), and tobramycin-MgATP complex (D). Tobramycin is a
competitive inhibitor for kanamycin-phosphate. In the binary complex (C), APH undergoes
significant structural changes compared to the apo-enzyme. In the ternary complex, APH(3’)IIIa exhibits a less structured spectrum than the binary complex23.

III. Theorell-Chance Kinetic Mechanism
APH(3’)-IIIa follows a Theorell-Chance kinetic mechanism, a rare form of an ordered
bi-bi kinetic mechanism. The Theorell-Chance mechanism follows an ordered substrate
binding and product release with a very small accumulation of the enzyme-substrate complex.
This specific mechanism contains a ternary complex but does not contribute to the overall rate
of the reaction. As the concentration increases for the first substrate, initial rates increase with
the concentration of the second substrate below the Km15,24,25.
11

For APH(3’)-IIIa, the chemical step of the reaction is defined as the binding of ATP
(first substrate bound), followed by the binding of an aminoglycoside. Phosphorylated
aminoglycoside is then rapidly released followed by the rate-limiting, slow release of ADP
(figure 8). These findings were observed with both classes of aminoglycoside antibiotics,
which is consistent with the Theorell-Chance mechanism where different substrates have little
effect on the overall rate of reaction considering that the phosphorylated aminoglycoside is
released prior to the rate-limiting step. At high substrate concentrations, substrate inhibition
was observed suggesting that nonproductive binding to the enzyme-ADP complex contributed
to the rate-limiting, ADP product release. Similarly, inhibition of ATP by kanamycin
phosphate was abolished by increased concentrations of kanamycin A25.

Figure 8: Theorell-Chance Mechanism for APH(3’)-IIIa25.

IV. Kinetic and Thermodynamic Properties
Isothermal Titration Calorimetry (ITC) studies have been conducted for APH(3’)-IIIa
with several 4,5- and 4,6-disubstituted 2-deoxystreptamine aminoglycosides. In general,
APH(3’)-IIIa binds to aminoglycosides with a favorable enthalpy and an unfavorable entropy
12

yielding an overall favorable Gibbs energy for the reaction. Both binary and ternary
complexes exhibit different thermodynamic properties with none correlating with the kinetic
parameters Km, kcat, or kcat/Km. In the binary complex, binding of an aminoglycoside is
mainly driven by an exothermic reaction with an unfavorable entropic contribution. The
unfavorable entropy of binding is likely to be due to the reduced conformational freedom
shown by the HSQC spectrum, where binding of aminoglycoside to APH(3’)-IIIa becomes
highly structured. This was shown to be the case for all aminoglycosides with no clear trends
distinguishing a difference between the 4,5- and 4,6-disubstituted aminoglycosides14,23.
Similar to the binary complex, formation of the ternary complex, APH(3’)-IIIaCaATP-aminoglycoside, exhibited exothermic heat and favorable Gibbs free energy for all
aminoglycosides. However, the ternary complex was observed to have a significantly lower
enthalpic contribution and a less unfavorable entropy contribution. These observations are in
agreement with the NMR data, where binding of a nucleotide increases the solvent
accessibility and weakens the bonds between the α-helix and β-sheet at the nucleotide-binding
interface. In general, the presence of CaATP induces tighter or unchanged binding of
aminoglycosides to APH(3’)-IIIa, which is in agreement with the suggested Theorell-Chance
kinetic mechanism24,23,26.
The kinetic parameters for APH(3’)-IIIa varied among aminoglycosides. In general,
the Km values were lower for 4,6-disubstituted aminoglycosides with the exception of
neomycin B and ribostamycin. General trends between the 4,5-disubstitued aminoglycosides
differing in the addition or absence of a functional group were observed. Butirosin and
ribostamycin only differ in their structure by the presence of a (S)-4-amino-2-hydroxybutyryl
group at the aminocyclitol N-1 (butirosin). The kcat/Km was shown to have a 3.4-fold decrease
for butirosin suggesting that the aminocyclitol ring plays a role in substrate orientation when
binding to APH(3’)-IIIa. It was also shown that the substitution of an amino group for a
hydroxyl group for kanamycin A and B affected the kinetic parameters. This further
supported the thermodynamic data by Ozen et al., where kanamycin B exhibited a 15-fold
increase in affinity. These data suggested that the 2’-amino group on kanamycin B may
participate in cooperative hydrogen bonding13,14,26.
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At high aminoglycoside concentrations, substrate inhibition was exhibited and more
pronounced for 4,5-disubstituted aminoglycosides. The large Ki values for all
aminoglycosides that exhibited substrate inhibition were suggested to have no biological
significance. Tobramycin (3-deoxykanamycin B) was shown to not be a substrate for
APH(3’)-IIIa but was a competitive inhibitor for kanamycin A13,14,26.

E. Introduction to Aminoglycoside -3-N-Acetyltransferase-IIIb
Aminoglycoside acetyltransferases (AAC) are some of the most diverse modifying
enzymes. N-acetyltransferases contain four classes based on regiospecificity of modification
on aminoglycosides at the 1-, 3-, 6’-, and 2’-amino group positions. These enzymes range in
size from 15-22kDa and catalyze the transfer of an acetyl group from Acetyl coenzyme A to
the respective amino groups, producing CoASH and N-Acetyl-aminoglycoside (Scheme 1).
The AAC(3) class is one of the largest groups of enzymes, approximately 30kDa, which
display significant homology in their N-terminal region. For this particular class, there are
eight genes (I-IX), each varying in substrate specificity across the kanamycin and neomycin
classes. AAC(3)-III contains three gene clusters one isolated from Pseudomonas aeruginosa
and two isolated from Pseudomonas strains. This subfamily acetylates the amino group at the
3-carbon position on the 2-deoxystreptamine ring (2-DOS). AAC(3)-IIIb is a homo-dimer
consisting of two active sites. This protein is one of the most promiscuous modifying
enzymes as it modifies both 4,5- and 4,6-disubstituted 2-deoxystreptamine aminoglycosides,
including tobramycin, kanamycin A, kanamycin B, gentamicin C, sisomicin, neomycin B,
paromomycin A, ribostamycin, and lividomycin6,12,27.

I. Protein Dynamics in Solution
A series of 1H-15N HSQC experiments were conducted for AAC(3)-IIIb apo-enzyme
and ligand-bound forms. In both forms, AAC(3)-IIIb exhibited a well defined structure. In
the apo-form, ~40-50 resonances were missing in the spectrum located near the antibiotic14

binding loop. These data suggested that AAC(3)-IIIb has a well defined protein structure with
a highly flexible antibiotic binding loop. The binding of CoASH to the first binding site
exhibited a small shift in peaks without broadening. Upon CoASH binding to the second site,
peak intensities increased but did not shift. Therefore, the vast majority of conformational
changes to AAC(3)-IIIb are mainly due to aminoglycoside binding (figure 9)27,28,29.

Figure 9: 1H-15N HSQC NMR spectra for AAC(3)-IIIb in the apo-form (left), AAC(3)-IIIbtobramycin complex (middle), and AAC(3)-IIIb-CoASH complex (right)30.

II. Kinetic and Thermodynamic Properties
From what is previously known about AGMEs, AAC(3)-IIIb is one of the few
enzymes that discriminate between the 4,5- and 4,6-disubstituted 2-DOS aminoglycosides.
The 4,6-disubstituted aminoglycosides have turnover rates (kcat) between 46s-1 and 55s-1
whereas the 4,5-disubstituted aminoglycosides have rates between 10s-1 and 34s-1. Therefore,
the kanamycin-like aminoglycosides are bound, acetylated, and released much faster than the
neomycin-like aminoglycosides. It was suggested that the difference in catalytic turnover
rates may be due to the orientation of the antibiotic within the active site of AAC(3)-IIIb.
Although amikacin and butirosin, both substituted at the N-1 position, can bind to the enzyme,
their kcat values did not show measurable rates. Bulky substitutions at the N-1 position were
thereby suggested to distort the orientation of the aminoglycoside at the antibiotic binding
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loop and hinder proper alignment of the N-3 amine group for acetylation. Overall, the
catalytic turnover rates for AAC(3)-IIIb with all substrates are among the highest observed for
AGMEs. In particular, aminoglycosides containing a 2’-amine group (tobramycin, kanamycin
B, and sisomicin) exhibited the highest specificity27,28.
At high concentrations of aminoglycosides, AAC(3)-IIIb exhibited substrate inhibition
with no correlation between Ki and Km values. In general, smaller and/or less constrained
aminoglycosides (kanamycin A, kanamycin B, ribostamycin, tobramycin) exhibited the
lowest substrate inhibition compared to larger or more sterically hindered aminoglycosides
(neomycin B, paromomycin, lividomycin A, and sisomicin)27,28.
Unlike the kinetic parameters that differentiated between the 4,6-disubstituted and 4,5disubstituted 2-DOS aminoglycosides, the thermodynamic parameters did not differentiate
between the two classes. Also, AAC(3)-IIIb was shown to have no correlation between the
thermodynamic and kinetic parameters. For all substrates, binding to AAC(3)-IIIb was shown
to be exothermic with a favorable intrinsic enthalpy and unfavorable intrinsic entropy yielding
an overall favorable Gibbs free energy. However, binding of kanamycin A in the binary
complex exhibited a less favorable intrinsic enthalpy and a more favorable intrinsic entropy.
In the presence of CoASH bound to one binding site in the ternary complex, a more favorable
enthalpy and less favorable entropy contributed to an overall increase of 1.0 kcal/mol - 1.9
kcal/mol in the Gibbs free energy. These data suggest that the binding of the cofactor to one
active site stabilizes the protein conformational state to position the antibiotic binding loop for
greater aminoglycoside binding. In general, binding of CoASH to one binding site increases
the binding affinity for aminoglycosides by 5-20 fold and is accompanied by a more favorable
intrinsic enthalpy and a less favorable entropy. The more negative enthalpic contribution has
been suggested to be caused by an increase in contacts made between the enzyme and
aminoglycoside27,28.
In the binary complex, AAC(3)-IIIb - aminoglycoside, smaller antibiotics bind to the
active site with a stoichiometry of 1.5-2 molecules per enzyme, while aminoglycosides with 4
or 5 modified amino sugar rings were shown to have a stoichiometry of 1 molecule per
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enzyme. This is likely to be the consequence of the large size of the aminoglycoside binding
pocket to which more than one of the smaller aminoglycosides can fit in various binding
modes. In the presence of CoASH, the stoichiometry for binding of all aminoglycosides to
AAC(3)-IIIb was shown to be one molecule per enzyme regardless of size of the substrate27.
Although there were no clear trends to distinguish between the 4,5- and 4,6disubstituted 2-DOS aminoglycosides, substitution patterns for aminoglycosides differed in
affinity for AAC(3)-IIIb. Aminoglycosides containing an amine group at the 2’-carbon
(kanamycin B, tobramycin, sisomycin) were shown to be more favorable than a hydroxyl
group at this position (kanamycin A). The presence of an amine group (neomycin B) versus a
hydroxyl group (paromomycin A) at the 6’-carbon was preferred for aminoglycosides of equal
size. The size of the aminoglycoside appeared to take precedent over the 6’-amine group
where lividomcyin (5 rings) and ribostamycin (3 rings) were observed to have weaker affinity
to AAC(3)-IIIb when compared to neomycin B (4 rings). This trend also held true for 4,6aminoglycosides (3 rings) containing a 6’-amine group, which was observed to also have a
decrease in affinity compared to aminoglycosides containing 4 rings27,29,31.

III. Proposed Orientation for Aminoglycosides in the Active Site
The orientations of 2-DOS aminoglycoside substrates in the active site of AAC(3)-IIIb
have been proposed from manual docking and homology modeling with crystal structures of
two proteins in complex with acetyl coenzyme A, both from Bacillus and members of the
antibiotic_NAT superfamily, YokD and AAC (3) (PDB 2NYG and 3IJW, respectively).
Within the antibiotic binding pocket, negatively charged side chains are positioned to interact
with amine groups of the antibiotic, placing the N-3 amine in a proximal position next to the
acetyl group of acetyl coenzyme A. The fourth ring of neomycin B may attract a carboxyl
side chain, thereby blocking other antibiotics from binding to the active site. Kanamycin A
appears to make similar contacts as neomycin B but the third ring may not be able to interact
as favorably as aminoglycosides with four or more rings. Therefore, it was suggested that the
weaker contacts made by kanamycin A would leave the antibiotic binding loop more exposed
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allowing similar structured aminoglycosides to bind. This hypothesis would provide an
explanation for the binding stoichiometry of >1 for smaller aminoglycosides27,28,30.

F. Introduction to Aminoglycoside -3-N-Acetyltransferase-VIa
AAC(3)-VIa is a rare isolate found in Gram-negative organisms, mainly in
Escherichia coli. This enzyme is 32kDa with a limited substrate profile capable of modifying
gentamicin C, sisomicin, 6’-N-ethylmetilmicin, tobramycin, netilmicin, and kanamycin B at
the N-3 position on the 2-deoxystreptamine ring. AAC(3)-VIa shows 48% sequence
homology to AAC(3)-IIa. Little characterization has been conducted for this enzyme and
studies are currently underway in the lab12,32.

G. Enzyme Characteristics for APH(3’)-IIIa, AAC(3)-IIIb, and AAC(3)-VIa
APH(3’)-IIIa, AAC(3)-IIIb, and AAC(3)-VIa exhibit significantly different protein
characteristics (table 1). In general, AAC(3)-IIIb has lower Km values and much greater
turnover rates compared to APH(3’)-IIIa. APH(3’)-IIIa binds to all aminoglycosides with a
stoichiometry of 1:1 whereas AAC(3)-IIIb varies in stoichiometry between 1-2 depending on
the aminoglycoside with the exception of kanamycin A that has a stoichiometry of 2.8. Both
APH(3’)-IIIa and AAC(3)-IIIb are highly promiscuous whereas AAC(3)-VIa has a limited
substrate profile and unable to bind to neomycin13,14,23,27,28,29.
Thermodynamically, APH and AAC(3)-IIIb both exhibit exothermic binding reactions
with a favorable enthalpy and unfavorable entropy contribution yielding an overall favorable
net free energy. The ternary complex for APH differs from AAC(3)–IIIb, where the observed
intrinsic enthalpy contribution is less favorable with a more favorable intrinsic entropy
contribution. The binding of cofactors to each enzyme exhibited similar trends but had a
more profound effect for AAC(3)-IIIb. When MgATP is bound to APH, there was a slight
increase in the affinity for aminoglycosides, whereas the binding of acetyl coenzyme A to
AAC(3)-IIIb greatly increased the affinity of substrates14,23,27,28,29.
18

Protein dynamics for APH and AAC(3)–IIIb exhibit various differences in the apoenzyme, binary, and ternary complex. APH was observed to be highly dynamic in the apoform and became structured when bound to an aminoglycoside. The presence of MgATP did
not significantly alter the structure of APH when the ternary complex was formed. Unlike
APH, the AAC(3)-IIIb apo-enzyme was well structured with a highly flexible antibiotic
binding loop. Titration with ligands cause small shifts in several resonances and changed
dynamics of several amino acids such that their resonances became visible in the
spectrum23,27,28,30.
While APH(3’)-IIIa and AAC(3)-IIIb are two highly promiscuous AGMEs with
similar substrate profiles, AAC(3)-IIIb catalyzes the modification reaction faster than
APH(3’)-IIIa. As stated above, Wolfenden et al. described in several studies that the rate
enhancement produced by catalysts is improved at lower temperatures and has a significantly
less positive ∆!‡ 1. Therefore, the purpose of this study is to determine the temperature
dependence of catalysis in the three enzymes. One caveat is whether the transition state for
the chemical step will be measured, as for example, the rate determining step in APH(3’)-IIIa
is release of the ADP product. The rate determining steps in the other two enzymes still need
to be determined. If chemistry is rate determining in any of the enzymes, we can examine
whether the kinetic barrier is lowered by the enthalpy of activation during the reaction. Also
of interest, the enthalpy of activation will also be studied with AAC(3)-VIa, a less
promiscuous enzyme, and AAC(3)-IIIb bound to gentamicin C1 and C2, two antibiotics with
the same structure that only vary by one methyl group. Here we propose that the activation
energy will differ between the two gentamicin components for both enzymes, where AAC(3)IIIb will favor the more hydrophobic gentamicin C1 while AAC(3)-VIa will favor gentamicin
C2.
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Table 1: Comparison of protein characteristics for APH(3’)-IIIa, AAC(3)-IIIb, and AAC(3)-VIa.
Enzyme

APH(3’)-IIIa13

b

Modification Reaction

ATPŊAGŊAPH(3' )-IIIa ↔
ADP·phospho-AG ŊAPH(3' )-IIIa

From AAC(3)IIIb27

AG+AcCoA

AAC(3)-VIa32

AG+AcCoA

AAC

AAC

a

Substrates

KanA, KanB,
NeoB, Prm, Amk,
Isep, Ribo, But,
Liv

AG-C O CH3 +CoASH

kanA, kanB, gnt,
siso, neoB, tob,
prm, ribo, liv

AG-C O CH3 +CoASH

kanB, gnt, siso,
tob, ntl, 6’ntl

Crystal
Structure
1L8T – KanA
3TMO – But
2B0Q - NeoB
1J7I – Apoenzyme
1J7L – ADP
1J7U - AMPPNP

kan A – 12.6±2.6
kanB – 19.4±2.2
amk - 245±27
neoB – 7.72±0.9
prm – 19.5±3.5
liv – 31.6±5.1
ribo – 9.30±1.8
but – 34.3±3.7
kan A – 4.8±0.5
kan B – 2.6±1.6
neoB – 1.2±0.2
prm – 3.3±0.6
liv – 3.6±0.1
tob – 1.3±0.8
siso – 1.5±0.4
NA

a

kcat (s-1)

Km (µM)

kcat/Km (M-1 s-1)

kanA – 1.79±0.09
kanb – 3.51±0.19
amk – 2.46±0.11
neoB – 2.08±0.07
prm – 3.62±0.25
liv – 3.97±0.25
ribo – 1.89±0.10
but – 2.02±0.07

kanA – 1.43 x 105
kanB – 1.81 x 105
amk – 1.00 x 104
neoB – 2.69 x 105
prm – 1.86 x 105
liv – 1.26 x 105
ribo – 2.03 x 105
but – 5.87 x 104

kan A – 51.4±4.4
kan B – 54.5±3.6
neoB – 9.5±1.8
prm – 33.6±1.4
liv – 33.8±1.4
tob – 47.8±4.8
siso – 46.3±2.2

kan A – 11.2±2.3 x106
kan B – 34.4±19.8 x106
neoB – 9.1±0.2 x106
prm – 10.8±2.5 x106
liv – 9.5±0.8 x106
tob – 60.5±34.6 x106
siso – 33.4±9.5 x106

NA

NA

Abbreviations for aminoglycoside antibiotics: kan A – kanamycin A; kan B – kanamycin B; gnt – gentamicin C complex; neoB –
neomycin; prm – paromomycin; amk – amikacin; Isep – isepamicin; ribo – ribostamycin; but – butirosin; liv – lividomycin; ntl –
netilmicin; 6’-ntl – 6’-N-ethylnetilmicin; tob – tobramycin; siso - sisomicin
b
APH(3’)-IIIa follows a Theorell-Chance kinetic mechanism with an ordered substrate binding and product release. ATP is first
bound to the enzyme followed by the aminoglycoside. The phosphorylated aminoglycoside is then released prior to the slow release
of ADP, which has been determined as the rate-limiting step in the reaction. The kinetic mechanisms for AAC(3)-IIIb and AAC(3)VIa has yet to be determined.
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CHAPTER II: GENTAMICIN C COMPLEX

A. Background

I. Origin and Structure
Gentamicin C complex is synthesized from Micromonospora purpurea, a Grampositive organism, and is produced as a mixture of components used to treat Gram-negative
bacterial infections. The main active components are gentamicin C1a, C1, and C2, which make
up about 80% of the complex while the remaining 20% are composed of minor components.
These three active components only differ in the degree of methylation on the 2,6diaminosugar on the purpurosamine ring (figure 10). The degree of methylation increases by
one methyl group: gentamicin C1 > gentamicin C2 > gentamicin C1a.5,33,34.
Individual components of gentamicin C are not commercially distributed; rather the
antibiotic is retailed as a complex with sulfate. In order to study the differences in activation
energy affected by the degree of methylation of each component, gentamicin C complex must
first be separated into its respective components. Separation of gentamicin C complex can be
achieved by various chromatography techniques, particularly ion exchange and thin-layer
chromatography due to the antibiotic being highly polar, negatively charged, and
hydrophobic.

II. CHSQC-TOSCY Experiments
Homonuclear Total Correlation Spectroscopy (TOCSY) in combination with Carbon
Heteronuclear Decoupled Single Quantum Coherence (CHSQC) is commonly used to analyze
the structure of polysaccharides. In a simple TOSCY experiment, each monosaccharide unit
is associated with a single 1H spin system allowing differentiation between resonances
belonging to a single monosaccharide unit. The addition of CHSQC pulse sequence identifies
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the correlation of nuclear spins between α-carbons. CHSQC – spectrum shows cross-peaks
correlating carbon resonances with their respective hydrogen atoms. Proton-proton
connectivity’s determined from TOCSY experiments were then used to make assignments of
carbon atoms 35,36 (figure 11).

Figure 10: Structure of gentamicin C complex42. Gentamicin complex is composed of a
mixture of components that are differentiated based on the degrees of methylation at the R1,
R2, and R3 positions.

B. Experimental Procedure

I. Separation of Gentamicin C Complex by Thin Layer Chromatography
Gentamicin C complex (30ng) was placed on 20x20 silica gel plates purchased from
Sigma and placed in a chamber pre-saturated with the mobile phase (3:2:1 methanol:
propanol: ammonium hydroxide). Plates were removed after the mobile phase saturated ¾ of
the silica gel plate. TLC plates were dried and samples were analyzed by ninhydrin spray
(2.0g ninhydrin, 100ml dH2O, 100ml 1-butanol, 100mL Acetic Acid) and heated at 100°C for
10 minutes.
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II. Separation of Gentamicin C Components, C1, C2, C1a
Gentamicin C complex separation protocol was modified from Thomas et al37.
Gentamicin C complex (80mg) was dissolved in 1.0mL of 2.0M NaCl solution and loaded
onto an ion exchange Whatmann Cellulose Phosphate P-11 column (1.0cm x 15cm). A linear
gradient composed of 60mL of 2.0M NaCl and 60mL of 2.2M NaCl was applied to the
column. Fractions (2ml) were collected and analyzed by thin layer chromatography on silica
gel G plates and ninhydrin spray37. Fractions with respective purified components were
lyophilized, dissolved in 1mL of dH2O, and loaded onto a Sephadex G-10 column (30ml of
resin slurry on a 1.0cm by 50cm column) for desalting. The column was washed with 40ml of
dH2O and 1mL fractions were collected and analyzed by thin layer chromatography with
ninhydrin spray. Desalting of purified gentamicin components on a Sephadex G-10 column
was performed twice to ensure the removal of all salt. Following the second desalting of
purified gentamicin components, compounds were lyophilized and stored at -20°C.

III. NMR Verification of Purified Gentamicin C Components by 1H 1D NMR, Total
Correlation Spectroscopy (TOCSY), and Carbon Heteronuclear Single Quantum Coherence
(CHSQC)
Purified gentamicin components were dissolved, lyophilized, and redissolved in D2O.
1

H 1D NMR, 2D CHSQC, and TOCSY NMR experiments were used to analyze the purified

gentamicin components. Coupled and decoupled CHSQC experiments were run at 25°C.
TOCSY experiments were run at 25°C with 15ms, 30ms, 50ms, and 80ms mixing times. 1H
1D NMR spectra were analyzed by Mestrenova NMR analysis and CHSQC and TOCSY
experiments were analyzed by Sparky35.
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C. Results and Discussion

I. Gentamicin C Complex Separation by Thin Layer Chromatography
Gentamicin C complex separation can be shown by thin-layer chromatography on
silica gel plates38,39. Various mobile phase mixture systems consisting of methanol, propanol,
and ammonium hydroxide were analyzed to determine the best ratio of components. For all
mixture systems, diluting ammonium hydroxide yielded a less pronounced separation. The
mobile phase consisting of 2:3:1 ratio of chloroform: methanol: ammonia hydroxide exhibited
the best separation for gentamicin and darkest spots on the silica gel plates (figure 12).

C1
C2
C1a

C1
C1

C2

C2
C1a

C1a

Figure 11: Determination of mobile phase components for thin layer chromatography on
silica gel plates. Gentamicin C complex (30ng) was placed on silica gel plates 1-2inches
apart. Various mobile phases were studied composed of 3:2:1 methanol:propanol: ammonium
hydroxide (left), 3:2:1 methanol:propanol:25%ammonium hydroxide (middle), and 1:1:1
methanol:propanol:16% ammonium hydroxide (right). The mobile phase consisting of 3:2:1
methanol:propanol:ammonium hydroxide (left) exhibited the best separation of gentamicin
components: gentamicin C1 (top), gentamicin C2 (middle), and gentamicin C1a (bottom).
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II. Separation of Gentamicin Components by Ion Exchange Chromatography
A majority of fractions contained a mixture of C1 and C2 components with the
exception of the first and last few fractions (figure 13). Gentamicin C1 was eluted in the first
four fractions followed by the elution of gentamicin C2, which was present in fractions 20-24.
Gentamicin C1a was not purified and was only eluted as a mixture containing gentamicin C2.
Additional purification attempts with fractions containing a mixture of components did not
yield significant separation. We observed that increasing the size of the ion exchange column
to purify more gentamicin did not provide significant separation of components. Also,
minimizing the molarity of the salt gradient did not improve the separation.
Once separated by ion exchange, a Sephadex G-10 column desalted purified
gentamicin components. The initial desalting of gentamicin components still contained a high
level of salt, indicated by 1H 1D NMR, which showed a high level of interference in the
spectrum. After the second round of desalting, the 1H 1D NMR showed sharper signals in the
spectrum. Separation of gentamicin C1 and C2 yielded small quantities of purified
components, 1.5mg and 0.65mg, respectively. The small quantities of gentamicin are most
likely due to the numerous purification steps required to separate and desalt purified fractions.
In addition to the several purification steps, samples were lyophilized after each round of
purification, also leading to the loss of product. There have been several previously published
methods of separation of gentamicin components. In particular, separations by a silica gel
column and High Performance Liquid Chromatography (HPLC) have been the most recent
methods described40,41. Both of these methods were tested to improve the separation and
increase the quantity of product but neither yielded sufficient separation of gentamicin
components. Other methods described for separation include derivatized gentamicin. These
methods were not studied due to the potential structural changes that may be induced by
derivatization40,41.
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C1
C2

Figure 12: Gentamicin Separation by ion exchange chromatography with an 2.0-2.2M NaCl
gradient.

III. Verification of Purified Gentamicin C1 and C2 Components by 1H 1D NMR, TOCSY, and
CHSQC 2D NMR Experiments
The structure of gentamicin C1 and C2 were analyzed by 1H 1D NMR to verify the
purity of each component (figures 14 and 15, respectively). Peak assignments in both
spectrums were assigned by the reference spectra determined by Deubner et al. and desulfated
gentamicin complex (figure 16)42,43,44. On the NMR spectra, the labeled peaks correspond
with the numbering of carbons shown in figure 10. There are two main differences in the
gentamicin C1 and C2 spectra correlating to the number of methyl groups present on the 6’carbon and 6’-amine group. Both components contain a methyl group on the 6’-carbon shown
at 1.2 ppm (H-26 and H-27). The 1H peak associated with the additional methyl group on the
6’-amine group for gentamicin C1 is present at 2.6ppm labeled as H-29 (figure 14). This peak
is not present in the gentamicin C2 spectrum, indicating the differences in the two compounds.
The additional methyl groups labeled as H-7 and H-9, are the present for all the components
in the gentamicin C complex. It is to be noted that the chemical shifts are not identical for the
gentamicin spectra.
Gentamicin C2 is epimeric at the 6’-carbon position. The two epimers are denoted as
gentamicin C2 and gentamicin C2a with R and S configurations, respectively. These two
epimers are purified as a single component and exhibit slight variations in the 1H 1D NMR
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spectrum (figure 15). The additional doublets of peaks at 1.2 ppm (H-26 and H-27) are
consistent with the reference spectra and correlate with the epimer structures42.
Total Correlation Spectroscopy (TOCSY) and 1H 13C HSQC coupled and uncoupled
spectra were analyzed to verify the results found from the 1H 1D NMR spectra. Peak
assignments for TOCSY and CHSQC spectra were identified similar to Cox et al.35. Both
spectra indicated the presence of two methyl groups associated with gentamicin C1 whereas
gentamicin C2 only contained the presence of one methyl group on the 6’-carbon. For
gentamicin C2, the TOSCY and CHSQC spectra confirmed that the additional peaks shown in
the 1H 1D NMR spectrum were due to epimeric carbon at the 6’-position and not from
impurities.

Figure 13: 1H 1D NMR spectrum of gentamicin C1 component in D2O at 25°C.
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Figure 14: 1H 1D NMR spectrum of gentamicin C2 component in D2O at 25°C.

Figure 15: 1H 1D NMR spectrum for desulfated gentamicin C complex at 25°C.
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CHAPTER III: TEMPERATURE-DEPENDENT KINETIC ASSAYS FOR
APH(3’)-IIIa, AAC(3)-IIIb, AAC(3)-VIa

A. Background

I. Coupled Catalyzed Reactions
Modification reactions of aminoglycosides catalyzed by APH and AAC family of
enzymes are coupled with pyruvate kinase/lactate dehydrogenase (PK/LDH) and 4,4’dipyridyl disulfide, respectively (scheme 1). In general, coupled assays involve the addition
of one or more enzymes to catalyze a reaction with one of the products produced by the
enzyme being observed to produce another product that can be directly detected45.
For APH, ATP is regenerated from ADP, one product produced by the catalyzed
reaction of APH, by pyruvate kinase, which produces pyruvate. The production of pyruvate is
used as a reactant to oxidize NADH by lactate dehydrogenase. The disappearance of NADH
is directly measured at 340nm and is proportional to the production of the phosphorylatedaminoglycoside. In theory, the regeneration of ATP by the coupled reaction with pyruvate
kinase will prevent the depletion of this substrate, thereby eliminating the potential reduction
in initial velocity of the catalyzed reaction by APH13.
The AAC assay does not involve an additional coupled enzyme but contains the
presence of 4,4’-dipyridyl disulfide, which is reduced by CoA to produce pyridine-4-thiolate.
The production of pyridine-4-thiolate and disappearance of the disulfide can both be
quantitatively measured at 324nm by UV-Vis spectrometry and are proportional to the
production of the acetylated-aminoglycoside45,46.
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Scheme 1: Coupled catalyzed reactions for the APH(3’)-IIIa (a) and AAC(3) families of
enzymes (b). APH(3’)-IIIa utilizes a PK/LDH coupled enzyme assay to measure the
oxidation of NADH at 340nm, which is proportional to the production of phosphorylated
aminoglycoside. The coupled reaction for the AAC(3) family of enzymes measures the
production of pyridine-4-thiolate at 324nm, which is proportional to the acetylatedaminoglycoside product.

II. Michaelis-Menten Plots
Michaelis-Menten kinetics describes the rate enhancement of the chemical reactions
catalyzed by an enzyme. In general, an enzyme in the presence of a substrate will form an
enzyme-substrate complex, which is followed by the decomposition of this complex to form
free enzyme and product (equation 1). Under rapid equilibrium conditions, initial velocity
rates increase with an increase in substrate and enzyme concentrations. At saturating substrate
concentrations, the maximum velocity (Vmax) for a catalyzed reaction is achieved (equation 2).
The Km of a reaction is determined by, !! =

!!"#
!

, where half of the active sites on the

enzyme are filled by a substrate. Catalytic turnover rates, the maximum number of substrate
molecules converted to product per second, can be determined by the relationship of
!!"# = !!"# /[!!"!#$ ] 1,2,3,4,47,48.

! + !!

!!

!" !

!!

! + !!!"##
Equation 1
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!=

!!"# ∗ !
(!! + !)
Equation 2

III. Determination of Gibbs Free Energy, Enthalpy, and Entropy of Activation
In 1889, Savente Arrhenius directly observed a relationship between rate constants and
temperature. Arrhenius plots are based on the collision theory that states that molecules must
possess enough kinetic energy to collide with one another to provoke product formation.
Arrhenius plots are obtained by plotting the natural log of the catalytic turnover rates as a
function of inverse temperature (K-1) yielding a linear relationship in the form of ! = !" + !.
The slope of the Arrhenius plot directly measures the activation energy (average kinetic
energy) required for a reaction to proceed to product; whereas the y-intercept of the Arrhenius
plot provides the pre-exponential factor (lnA), which can be used to determine the rate
!!

constant from the Arrhenius equation, !!"# = !! !!" , where R is the gas constant. The Gibbs
free energy of activation can be described by: ∆! ‡ = ! −!"#$(!!"# ‡ ℎ/!! !), where h is
Planck’s constant and kB is the Boltzmann constant. The activation energy of a reaction is
analogous to the enthalpy of activation by the Eyring equation: !! = ! ∆!‡ ! + !". The
activation energy can be obtained from the slope (equation 3). From the thermodynamic
relationship, ∆! ‡ = ! ∆!‡ − !∆! ‡ , the entropy of activation for the reaction to the transition
state can be determined1,2,3,4,47,49,50.

Slope=

-Ea
R
Equation 3
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B. Experimental Procedure

I. Chemicals and Reagents
All chemicals and reagents used were of the highest purity. Aminoglycoside
antibiotics, adenosine 5’-triphosphate (ATP), and other chemicals required for kinetic activity
assays and protein were obtained from Sigma (St. Louis, MO). Sepharose Ni2+ NTA resin
was obtained from GE Healthcare and High MacQ anion exchange column resin was obtained
from BioRad. Kinetic assays were conducted using a Varian Carey 50Bio UV-Vis
spectrophotometer and temperature was controlled using a Brinkmann Lauda RM6 circulating
water bath system.

II. Purification of APH(3’)-IIIa
APH (3’)-IIIa was expressed in Escherichia coli BL21 (DE3) containing the
overexpression plasmid pETPCR6 provided by Dr. Gerard D. Wright, and was recloned to
include an N-terminal 6-his-tag. APH (3’)-IIIa was purified using a modified protocol
described by McKay et al13. Colonies were grown at 37°C overnight on Luria broth (LB) agar
from a 20% glycerol stock. A 10ml subculture was inoculated from one colony in LB broth
containing 0.1mg/ml ampicillin and grown overnight at 37°C with shaking. Two liters of
(LB) media containing 0.1mg/ml of ampicillin were inoculated with 20ml from the overnight
subculture and grown at 37°C with shaking. Growth of cells was monitored by OD600 every
hour until mid log phase was reached (0.6-0.8 absorbance). Protein expression was induced
with 1mM IPTG for four hours and harvested by centrifugation at 6,000xg for 15 minutes at
4°C. Harvested cells were washed with 0.85% NaCl solution, centrifuged at 6,000xg at 4°C,
and prepped for lysis. Cell pellet was solubilized in 20mL of lysis buffer (50mM Tris-HCL
pH 7.6, 100mM NaCl, 20mM Imidazole, 100mM phenylmethylsulfonyl fluoride (PMSF)) and
lysed with 3 passes of the French Press at 15,000 psi. The lysate was centrifuged at 35,000xg
for one hour to remove cell debris. Lysate was loaded onto a Sepharose Ni2+ NTA column
(1.5mL slurry resin in 1.5x5 column) and washed with 150mL of wash buffer (50mM Tris32

HCL pH 7.6, 100mM NaCl, 20mM Imidazole). Purified protein was eluted using a step
gradient consisting of 15ml wash buffer (50mM Tris-HCL pH 7.6, 100mM NaCl, 100mM
Imidazole) and 10mL of elution buffer (50mM Tris-HCL pH 7.6, 100mM NaCl, 500mM
Imidazole) and dialyzed 3 times against 350ml of dialysis buffer (50mM Tris-HCL pH 7.6,
100mM NaCl) for 1.5 hours. The N-terminal 6-His tag was removed by thrombin, 1:750 ratio
of thrombin to protein (w/w) for one hour at room temperature with light shaking and
reloaded onto a Sepharose Ni2+ column. Flow through containing purified protein was
measured at 280/260nm ratio. Purified protein was loaded onto a high MacQ anion exchange
column using Fast Protein Liquid Chromatography (FPLC). Protein fractions (2ml) were
eluted using a linear gradient (0.1M to 2M NaCl, 50mM Tris-HCL pH 7.6) with a flow rate
of 2.0ml/min and collected with a fraction collector. Purified protein fractions were verified
by SDS-PAGE electrophoresis. Protein was dialyzed against 350ml of dialysis buffer 3 times
for 1.5hours and stored at -80°C in 1ml aliquots.

II. Purification of AAC(3)-IIIb
Purified AAC(3)-IIIb (46.8µM) was kindly provided by Sherin Raval, a recent
member of the lab. Before conducting kinetic assays, protein activity was verified to be equal
to the original activity (63.5µmol/min*mg). The protein purification procedure used by Raval
was adopted from the original procedure written by Owston et al. and Norris et al27,31.
AAC(3)-IIIb was originally isolated from Pseudomonas aeruginosa [provided by Dr. George
Miller and Karen Shaw of Schering Plough] and transformed into a pET22b plasmid vector
containing a N-terminal 6-his-tag and was expressed by Escherichia coli BL21 (DE3) cells.
Transformed cells were first overexpressed by inoculating 1ml of LB broth with a single
colony of cells grown on agar plates containing 0.1mg/ml ampicillin for 6-8hours at 37°C
with shaking. From the initial inoculation, an overnight culture containing the initial 1ml
inoculation and 0.1mg/ml ampicillin was grown overnight for 18-24hours at 37°C with
shaking. The overnight culture was added to fresh LB media containing 01.mg/ml ampicillin
and grown at 37°C with shaking. Cell growth was monitored every hour by OD600 until mid
log phase was reached at an absorbance between 0.6-0.8. At mid log phase, 1mM of IPTG
was added to protein overexpression and grown for an additional 4 hours. Cells were
33

harvested by centrifugation at 6,000xg for 13 minutes at 4°C. The harvested cell pellet was
resuspended and washed with 150ml of 0.85% NaCl, centrifuged at 6,000xg at 4°C, and
prepped for cell lysis. Cells were resuspended in 15ml of lysis buffer (100mM PMSF, 50mM
Tris-HCL pH 7.6, 100mM NaCl, 20mM Imidazole) and homogenized. Cells were lysed with
3 passes of the French press at 15,000 PSI and centrifuged at 35,000xg for 1 hour. Crude
lysate was loaded onto a Sepharose Ni2+ NTA column (1.5ml resin slurry onto a 5x5 column).
Column was initially washed with 150ml of wash buffer (50mM Tris-HCL pH 7.6, 100mM
NaCl, 20mM Imidazole). Protein was eluted with 40ml of 50mM Tris-HCL, pH 7.6, 100mM
NaCl, and an Imidazole gradient from 100mM to 350mM by a 100ml gradient maker. Protein
fractions (2mL) were collected and measured for purity (1:40 dilution) at 280/260 on a
CaryWin UV-Vis Spectrophotometer. Purified protein fractions (1.4 or higher absorbance
ratio) were pooled and dialyzed against 350ml of dialysis buffer #1 (50mM Tris-HCL pH 7.6,
100mM NaCl) three times for 1.5hours. Thrombin, 1:100 ratio of thrombin to protein (w/w),
was added and incubated for 3 hours at room temperature with gentle shaking. Protein
containing thrombin was reloaded onto the Sepharose Ni2+ column and washed with 10ml of
wash buffer. Flow through was collected and analyzed on CaryWin UV-Vis
spectrophotometer to determine the 280/260nm ratio. Purified protein was dialyzed against 3
changes of 350ml of dialysis buffer #2 (50mM Tris-HCL, pH 8.0) for 1.5hours. To remove
the remaining salt, protein was loaded onto a MacroPrep Q anion exchange column (25ml
resin slurry in a 1.5x25 column). Protein was loaded onto the anion exchange column and
washed with 50ml of ion exchange wash buffer (50mM Tris-HCL, pH 8.0). Purified protein
was eluted by 50ml salt gradient containing 50mM-Tris-HCL pH 8.0 and increasing salt
concentration from 0-700mM NaCl. Protein fractions were collected in 3-4ml fractions and
verified by 280/260nm ratio and SDS-PAGE electrophoresis. Purified protein was dialyzed 3
times with 500ml dialysis buffer #2 for 1.5hours. Aliquots containing 1ml of protein were
stored at -80°C.

III. Purification of AAC(3)-VIa
Purified AAC(3)-IIIb (49.0µM) was kindly provided by Prashasti Kumar, a current
member of the lab. Before conducting kinetic assays, protein activity was verified to be equal
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to the original activity. AAC(3)-VIa was transformed into a pET15b plasmid vector
containing a N-terminal 6-his tag by GeneScript. Plasmid was transformed and overexpressed
into E. coli BL21 (DE3) cells. Colonies were grown on agar plates overnight at 37°C. A
subculture grown in LB media containing 0.1mg/ml ampicillin was inoculated with a single
colony and incubated at 37°C with shaking at 200rpm overnight. The overnight culture was
added to fresh LB media containing 0.1mg/ml ampicillin and grown at 37°C with shaking at
200rpm until mid log phase was reached at OD600 0.6-0.8 absorbance. Protein overexpression
was induced with 0.5mM of IPTG for 3.5 hours at 37 °C with shaking at 200rpm. Cells were
harvested by centrifugation at 6,000xg for 15 minutes at 4°C. Cell pellet was resuspended
with 0.85% NaCl and centrifuged at 4°C for an additional 15 minutes at 6,000xg. Cell pellet
was resuspended in 25ml of lysis buffer (100mM PMSF, 50mM Tris-HCL pH 7.6, 100mM
NaCl, 20mM Imidazole) and lysed by 3 passes of the French Press at 15,000 PSI. Lysate was
centrifuged at 4°C for 1 hour at 35,000xg. Lysate was loaded onto a Sepharose Ni2+ column
(1.5ml resin slurry in 1.5x5 column) and washed with 150ml of wash buffer (50mM Tris-HCL
pH 7.6, 100mM NaCl, 20mM Imidazole). Protein was eluted with 15ml of elution buffer
(50mM Tris-HCL, pH 7.6, 100mM NaCl, 300mM Imidazole) with 5-6ml fractions collected.
Fractions were analyzed on a CaryWin UV-Vis spectrophotometer at 280/260nm ratio.
Purified protein was dialyzed against 1L of dialysis buffer (50mM Tris-HCL pH 8.0, 100mM
NaCl) 3 times for 1.5 hours at 4°C. The N-terminal 6-His-tag was cleaved by thrombin, 1:750
ratio of thrombin to protein (w/w), with 50mM MOPS for 4 hours at room temperature with
light shaking. Protein was reloaded onto a Sepharose Ni2+ column and washed with 10ml of
dialysis buffer. Flow through was collected in 2-3ml fractions and absorbance was monitored
at 280/260nm. Protein was dialyzed against 1L of 50mM Tris-HCL pH 8.0 3 times for 1.5
hours. Dialyzed protein was loaded onto a MacroQ anion exchange column (1.5x25 column)
and washed with 2 column volumes of ion exchange buffer A (50mM Tris-HCL pH 8.0).
Protein was eluted by a 0-1M salt gradient and 2ml fractions were collected. Purified protein
fractions were determined by SDS-PAGE electrophoresis, dialyzed again with 1L of 50mM
Tris-HCL pH 8.0 buffer 3 times for 1.5hours, and stored at 4°C.
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IV. Kinetic Assays for APH(3’)-IIIa
APH(3’)-IIIa activity assay protocol was adapted from McKay et al13.
Phosphorylation of aminoglycoside antibiotics was monitored by the coupled enzymatic assay
by measuring the production of NAD+ converted by Kinase/lactate dehydrogenase (PK/LDH)
reaction (scheme 1A). Oxidation of NADH was monitored at 340nm absorbance, which is
proportional to the production of phosphorylated aminoglycoside. Assay mixture was
composed of assay buffer (50mM Tris pH 7.6, 100mM KCl, 1.5mM MgCl2, 150µM NADH,
2mM phosphoenolpyruvate, 1mM ATP), various concentrations of aminoglycoside
antibiotics, and 5uL of PK/LDH (0.02mg/ml) enzyme solution for a total volume of 1ml. The
mixture was pre-incubated at various temperatures for 15 minutes and initiated by a rapid
addition of purified APH(3’)-IIIa (32.5µM) stock solution. Initial rates were obtained from
enzymatic reaction curves and analyzed by Michaelis-Menten fitting (equation 2) in Prism
Graphpad 6.0 software.

V. Kinetic Assays for AAC(3)-IIIb and AAC(3)-VIa
AAC(3)-IIIb and AAC(3)-VIa catalyzed modification reaction was measured using a
coupled assay (scheme 1B)31. The product formation of pryridine-4-thiolate was measured at
324nm absorbance, which was proportional to the production of acetylated aminoglycoside.
Assay mixture was composed of assay buffer (50mM Tris-HCL pH 7.6, 100mM NaCl,
750µM Aldiothiol, 100µM Acetyl CoA, 100mM EDTA) and various concentrations of
aminoglycoside antibiotics for a total volume of 1ml. The mixture was pre-incubated at
various temperatures for 15 minutes and initiated by a rapid addition of purified AAC(3)-IIIb
or AAC(3)-VIa (1 µM) stock solution. Initial rates were obtained from enzymatic reaction
curves and analyzed by Michaelis-Menten fitting (equation 2) in Prism Graphpad 6.0
software.
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C. Results and Discussion

I. Kinetic Assays for APH(3’)-IIIa, AAC(3)-IIIb, and AAC(3)-VIa
Michaelis-Menten plots were used to determine the kinetic parameters for APH(3’)IIIa, AAC(3)-IIIb, and AAC(3)-VIa with various aminoglycosides at a temperature range
between 10°C to 37°C (table 2). For all three enzymes, there was no problem with the
coupled reaction. For the coupled reaction with APH(3’)-IIIa, the concentration of APH(3’)IIIa was doubled with 100µM aminoglycoside concentration. When the concentration of
APH(3’)-IIIa was doubled, the initial rates were remained the same. In theory, the coupled
reaction with PK/LDH is a 1:1:1 ratio. Therefore, doubling the concentration of APH(3’)-IIIa
should not affect the initial velocity rates when measuring the amount of phosphorylated
aminoglycoside. For the coupled reaction with AAC(3)-IIIb and AAC(3)-VIa, the
concentration of AAC(3)-IIIb or AAC(3)-VIa was doubled with 100µM aminoglycoside.
When the initial rates were doubled for either enzyme, the initial velocity rates were
proportional to the rates at standard conditions.
The initial rates for the catalyzed reactions with all three enzymes were observed to
decrease at lower temperatures. To compensate for the decrease in rate, the concentration for
all three enzymes was increased by at least 1µM. However, the increase in enzyme
concentration was not consistent for all three enzymes and depended on which substrate was
being studied.
The chemical and rate-limiting step for APH(3’)-IIIa has been previous determined to
be the binding of ATP and the release of the second product, ADP, respectively. The ratelimiting step for both AAC(3) enzymes has yet to be determined. These enzymes may exhibit
similar kinetic mechanisms to those been previously determined for two other aminoglycoside
– 3 – N – acteyltransferases, AAC(3)-IVa and AAC(3)-I51,52. AAC(3)-IVa and AAC(3)-I
were shown to exhibit a random sequential kinetic mechanism, where both substrates must
first bind to the enzyme in order for catalysis to occur. For both enzymes, AAC(3)-IVa and
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AAC(3)-I, a preferred order of substrate binding was proposed, depending on the affinity for
the aminoglycoside and acetyl coenzyme A concentration, where acetyl coenzyme A is bound
first followed by the binding of the aminoglycoside51,52.
The kinetic parameters for all three enzymes exhibited a general trend with a decrease
in Vmax as temperature decreased. The Km values were expected to follow this similar trend
but this behavior was not observed. However, the determined Km values did fall within the
previously reported range of Km values13,27. The inconsistent decrease in Km values may be
due to variability within the assay and few substrate concentrations below the measured Km
values. The kinetic assays with APH(3’)-IIIa and paromomycin showed the largest
discrepancies between Km values with little variation with the temperature. Assays at 30°C
were repeated and additional temperatures close in range were performed for better fitting of
the Arrhenius plot.
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Table 2: Temperature-dependent kinetic parameters for APH(3’)-IIIa, AAC(3)-IIIb, and
AAC(3)-VIa with numerous aminoglycoside antibiotics at various substrate concentrations
and temperatures ranging from 10°C -37°C.
Aminoglycoside
APH(3’)-IIIa
Kanamycin A
Kanamycin A
Kanamycin A
Kanamycin A
Kanamycin A
Kanamycin A
Paromomycin
Paromomycin
Paromomycin
Paromomycin
Paromomycin
Paromomycin
Paromomycin
Paromomycin
Paromomycin
Paromomycin
Ribostamycin
Ribostamycin
Ribostamycin
Ribostamycin
Ribostamycin
Ribostamycin
Neomycin B
Neomycin B
Neomycin B
Neomycin B
Neomycin B
AAC(3)-IIIb
Neomycin B
Neomycin B
Neomycin B
Neomycin B
Neomycin B
Neomycin B

°C

a

Km (µM)

a

kcat (s-1)

kcat/Km (M-1 S-1)

37
30
25
21
15
12
37
36
30
30
26
25
21
20
15
10
37
30
25
21
15
12
37
30
25
18
10

12±2
21±4
6.0±1
8.9±1
14±4
9.0±3
14±3
32±15
17±7
16±4
14±7
6.3±2
5.8±1
17±6
16±2
8±4
48±23
31±10
9.2±5
5.5±1
5.9±2
14±5
2.9±1
4.7±1
3.2±1
2.6±1
3.8±1

1.9±0.1
1.0±0.2
0.5±0.04
0.3±0.03
0.3±0.04
0.1±0.02
1.2±0.2
2.1±1
1.0±0.4
0.9±0.2
0.8±0.4
0.5±0.1
0.2±0.02
0.4±0.2
0.3±0.04
0.1±0.03
3.0±2
1.6±0.6
0.7±0.3
0.4±0.04
0.2±0.04
0.2±0.05
1.1±0.1
0.5±0.1
0.4±0.1
0.2±0.03
0.1±0.02

1.50E+05
4.86E+04
8.64E+04
3.74E+04
1.86E+04
1.31E+04
8.80E+04
6.63E+04
5.90E+04
6.08E+04
5.40E+04
7.36E+04
3.30E+04
2.61E+04
1.71E+04
1.07E+04
6.30E+04
5.24E+04
7.81E+04
7.98E+04
3.18E+04
1.15E+04
3.72E+05
1.16E+05
1.25E+05
7.27E+04
2.45E+04

35
30
25
20
15
12

2.3±1
7.7±2
3.0±1
1.7±0.3
3.6±1
0.6±0.1

6.6±0.7
7.2±1
5.0±0.9
4.0±0.3
2.0±0.3
1.1±0.04

2.94E+06
9.36E+05
1.68E+06
2.38E+06
5.63E+05
2.07E+06
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Table 2: Continued.
Aminoglycoside
Kanamycin A
Kanamycin A
Kanamycin A
Kanamycin A
Kanamycin A
Paromomycin
Paromomycin
Paromomycin
Paromomycin
Paromomycin
Ribostamycin
Ribostamycin
Ribostamycin
Ribostamycin
Ribostamycin
Gentamicin C2
Gentamicin C2
Gentamicin C2
Gentamicin C2
Gentamicin C2
Gentamicin C1
Gentamicin C1
Gentamicin C1
Gentamicin C1
AAC(3)-VIa
Gentamicin C2
Gentamicin C2
Gentamicin C2
Gentamicin C2
Gentamicin C2
Gentamicin C1
Gentamicin C1
Gentamicin C1
Gentamicin C1
a

a

°C
37
30
25
19
10
37
30
25
18
12
37
30
25
18
12
37
30
25
18
12
30
25
18
12

Km (µM)
46±8
20±3
7.6±1
4.3±1
2.5±1
6.5±2
6.3±2
5.3±1
1.9±1
1.8±1
24±5
12±3
16±1
5.7±1
4.6±0.3
5.7±1
2.8±0.4
2.7±1
3.1±0.3
2.0±0.3
3.7±0.4
3.9±2
2.9±1
3.1±1

37
30
25
18
12
30
25
18
12

1.6±0.2
2.6±1
0.6±0.1
1.1±0.2
1.7±1
3.8±1
2.2±0.5
2.0±0.4
2.4±1

a

kcat (s-1)
125±21
78±8
46±4
21±1
9.0±1
32±4
24±4
20±2
11±1
8.6±2
33±5
23±4
20±2
10±0.9
7.3±0.3
50±6
41±2
35±3
24±1
19±0.9
24±1
25±7
21±3
17±4

kcat/Km (M-1 S-1)
2.72E+06
3.93E+06
6.04E+06
4.86E+06
3.64E+06
4.91E+06
3.88E+06
3.66E+06
5.88E+06
4.87E+06
1.40E+06
2.02E+06
1.24E+06
1.69E+06
1.59E+06
8.74E+06
1.47E+07
1.26E+07
7.53E+06
9.32E+06
6.55E+06
6.41E+06
7.53E+06
5.46E+06

13±1
12±3
11±0.4
8.3±0.7
5.1±1
17±1
11±1
10±0.8
6.5±1

8.45E+06
4.71E+06
1.89E+07
7.69E+06
3.07E+06
4.47E+06
5.20E+06
5.13E+06
2.74E+06

Error calculations for Km and kcat values were determined by Prism GraphPad 6.0.
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II. Activation Energies for APH(3’)-IIIa with various 4,5- and 4,6-disubstituted Aminoglycosides
Table 3: Thermodynamic activation parameters for APH(3')-IIIa, AAC(3)-IIIb, and AAC(3)-VIa. Enthalpy, entropy, and free energy
of activation were determined at 25°C. The activation energy was determined by the slope of the Arrhenius plot (equation 3).
a

APH(3')-IIIa
kanamycin A
neomycin B
paromomycin
ribostamycin
AAC(3)-IIIb
kanamycin A
gentamicin C1
gentamicin C2
neomycin B
paromomycin
ribostamycin
AAC(3)-VIa
gentamicin C1
gentamicin C2
a

!! !(!"#$!/!"#)

a

!!"#! (! !! )!"℃

‡
∆!!"℃
!(!"#$/!"#)

‡
∆!!"℃
!(!"#$/!"#)

‡
!∆!!"℃
!(!"#$/!"#)

18±1
16±0.3
18±1
22±0.6

0.6±1
0.4±1
0.6±1.2
0.8±0.6

18±1
18±0.3
18±1
17±0.6

17±1
15±0.3
17±1
21±0.6

-0.5±1
-2.9±0.4
-0.4±2
3.3±1

18±0.5
3.5±0.5
7.1±0.2
17±1
9.6±0.4
11±0.5

41±0.5
24±0.5
33 ±0.2
5.1±0.3
17±0.4
17±0.5

15±0.5
16±0.5
16±0.2
17±1
16±0.4
16±0.5

15±0.5
17±0.5
16±0.2
15±1
16±0.4
16±0.5

0.1±2
1.2±0.7
1.0±0.3
-1.1±2
-0.1±0.6
-0.1±0.7

8.2±1
6.4±0.6

13±1
9.6±1

16±1
16±0.6

17±1
17±0.6

0.9±1
0.8±1

Calculated errors for the activation energy (Ea) and kcat values were determined by Prism Graphpad 6.0.
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The activation energies for APH(3’)-IIIa were determined for kanamycin A, neomycin
B, ribostamycin, and paromomycin (table 3). There were no significant trends differing
between the 4,6- and 4,5-di-substituted aminoglycosides. These data also agree with previous
findings where the turnover rates and thermodynamic parameters did not distinguish between
the kanamycin-like and neomycin-like classes of aminoglycosides13,14. The slopes of the
Arrhenius plots were extrapolated and shown to intersect at similar temperatures ranging from
-5°C to 12°C, at which APH(3’)-IIIa was able to modify all substrates equally fast (figure 17).
The order of decreasing activation energy and catalytic turnover rates at 25°C for substrates
was ribostamycin > paromomycin ≥ kanamycin A > neomycin B. Kanamycin A (three
modified amino-sugar rings) and paromomycin (four modified amino-sugar rings) exhibited
similar activation energies and identical turnover rates. Due to the similar activation energies
for kanamycin A and paromomycin, it may be suggested that APH(3’)-IIIa does not prefer a
particular size of substrate in order to reduce the activation energy. This differs from previous
thermodynamic data where the size of aminoglycosides was proposed to influence the
thermodynamic parameters for the formation of the ternary complex14.
Ribostamycin was observed to have the least favorable enthalpy of activation
accompanied by a more favorable entropy of activation. These observations correlate with the
thermodynamic parameters in the formation of the ternary complex where ribostamycin
exhibited a less favorable intrinsic enthalpy compared to other 4,5-disubstituted 2-DOS
aminoglycosides. It was suggested that the fourth rings of 4,5-disubstituted aminoglycosides
(neomycin B and paromomcyin) contribute to the binding within the active site14,15. These
observations suggest that the more positive ∆!‡ associated with ribostamycin may be due to
additional breaking of bonds at the transition state to adopt a certain conformation. In doing
so, a more positive !∆! ‡ may be due to the rearrangement of solvent to yield similar ∆! ‡
values for the substrates studied. On the other hand, neomycin B was observed to exhibit a
less positive ∆!‡ and a negative !∆! ‡ value. This may be due to a more structured transition
state when bound to neomycin B53,54,55.
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Figure 16: Arrhenius plots for APH(3’)-IIIa with kanamycin A( red), neomycin B (blue),
parmomycin (green), and ribostamycin (magenta). There were no significant trends in
activation energy distinguishing the 4,5-disubstituted and 4,6-disubstituted aminoglycosides:
ribostamycin>parmomycin≥kanamycin A>neomycin B.

III. Activation Energy for AAC(3)-IIIb with Various Aminoglycosides
The activation energies for AAC(3)-IIIb were determined for kanamycin A,
gentamicin C1, gentamicin C2, neomycin B, paromomycin, and ribostamycin (table 3). Similar
to APH(3’)-IIIa, there were no significant trends in the activation energies that distinguished
between the 4,5- and 4,6-disubstituted aminoglycosides: gentamicin C1 > gentamicin C2 >
paromomycin > ribostamycin > neomycin B > kanamycin A. This agrees with the previously
reported data, which illustrated that there were no significant trends distinguishing between
the two classes of aminoglycosides based on the thermodynamic parameters but did show a
difference between the two classes in the overall catalytic turnover rates, which was lower for
the 4,5-disubstituted aminoglycosides27.
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In general, both gentamicin components had the shallowest slopes, whereas
kanamycin A had the steepest slope (figure 18). Both gentamicins carry hydrophobic methyl
groups, which are absent in kanamycin A, neomycin B, paromomycin, and ribostamycin. It
may be suggested that an increase in hydrophobicity may contribute to a decrease in
activation energy for AAC(3)-IIIb. From homology modeling, AAC(3)-IIIb contains several
nonpolar and hydrophobic residues that line the antibiotic binding site (figure 19). These
residues may increase the number of interactions with the primed ring of gentamicin, which
makes the most important contacts within the active site, allowing the orientation of the
antibiotic to be better optimized for catalysis27,28,29.

Figure 17: Arrhenius plots for AAC(3)-IIIb with kanamycin A( red), gentamicin C1 (black),
gentamicin C2 (orange), neomycin B (blue), parmomycin (green), and ribostamycin
(magenta). There were no significant trends in activation energy distingiushing the 4,5disubstituted and 4,6-disubstituted aminoglycosides with the Arrhenius slopes each substrate
interacting at a wide range of temperatures.
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Figure 18: A cartoon representation of the homology model of AAC(3)-IIIb from AAC(3) in
complex with CoASH (PDB: 3IJW) from Bacillus. The lining of the antibiotic binding loop
has been proposed to contain hydrophobic residues (green) and three tyrosine residues
(yellow)27.

The thermodynamic activation parameters were fairly consistent for all
aminoglycosides. The gentamicin components had the least favorable free energy of
activation due to a slightly more positive enthalpy of activation, which was compensated with
a slightly positive entropy of activation. Although there have been no structural or
thermodynamic studies conducted with AAC(3)-IIIb and the gentamicin components, the
slightly positive entropy of activation may suggest an increase in the degrees of freedom of
the ternary complex at the transition state if the kcat is shown to monitor the chemical step
53,54,55

. This may be attributed to the potential increase in hydrophobic and nonpolar residues

lining the active site on the antibiotic binding loop, which would promote more interactions
with the gentamicin primed ring and an increase in the rearrangement of solvent27,28,29.
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The 4,5-disubstituted aminoglycosides were observed to all have a slightly negative
entropy of activation while the 4,6-disubstituted aminoglycosides all exhibited a slightly
positive entropy of activation. When comparing neomycin B to kanamycin A, the enthalpies
of activation are nearly the same with a ~1kcal/mol difference in the free energy of activation.
When comparing the 4,6-disubstituted aminoglycosides, the highest activation energy
correlated with the fastest turnover rates: kanamycin A > gentamicin C2 > gentamicin C1.
When the slopes on the Arrhenius plots are extrapolated, kanamycin A was observed to be
modified equally as fast as gentamicin C1 and C2 at temperatures 18°C and 21°C, respectively;
whereas gentamicin C2 and gentamicin C1 were observed to be modified at equivalent rates at
10°C (figure 20). The enthalpy and entropy of activation for all three 4,6-disubstituted
aminoglycosides were fairly similar while the catalytic turnover rates measured at 25°C
varied. Therefore, the differences in activation energies for 4,6-disubstituted aminoglycosides
may be due to the orientation of the aminoglycoside in the active site, which allows AAC(3)IIIb to catalyze the reaction more quickly for gentamicin components than for kanamycin A.
When comparing the 4,5-disubstituted aminoglycosides, these substrates all had
similar activation energies, neomycin B > ribostamycin > paromomycin, which was
proportional to the catalytic turnover rates measured at 25°C. The correlation between lowest
activation energy and highest catalytic turnover rate was only observed for AAC(3)-IIIb
bound with 4,5-disubstituted aminoglycosides. When extrapolating the linear regression line,
neomycin B was modified equally as fast as paromomycin and ribostamycin at higher
temperatures, 60°C and 68°C, respectively; whereas ribostamycin and paromomcyin were
modified equally as fast at cooler temperatures around 30°C (figure 21). All three substrates
exhibited similar enthalpies of activation and slight negative entropies of activation.
Neomycin B was observed to have ~1kcal/mol more positive free energy of activation
compared to paromomycin and ribostamycin. Previous data suggested that the size of the
aminoglycoside and presence of a 6’-amine group influences the affinity of the substrate to
AAC(3)-IIIb. The activation energies do not appear to correlate with these findings, where
ribostamycin, the smallest of the 4,5-aminoglycosides studied, and paromomycin, containing
a 6’-hydroxyl group, exhibited a lower activation energy compared to neomycin B27,28.
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Figure 19: Arrhenius plots for AAC(3)-IIIb with kanamycin A( red), gentamicin C1 (black),
and gentamicin C2 (orange). AAC(3)-IIIb modified both genamicin components at 10°C
while kanamicin A was modified as quickly as gentamicin C1 and C2 at 18°C and 21°C,
respectively.
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Figure 20: Arrhenius plots for AAC(3)-IIIb with neomycin B (blue), parmomycin (green),
and ribostamycin (magenta). The Arrhenius slopes intersected at much greater temperature
ranges compared to the 4,6-disubstituted aminoglycosides. AAC(3)-IIIb modifies neomycin
B equally as fast as paromomycin and ribostamycin at temperatures 60°C and 68°C,
respectively, whereas paromomycin and ribostamycin are modified equally as fast at 30°C.
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III. Activation Energy for AAC(3)-VIa with Gentamicin C1 and C2
The activation energy for AAC(3)-VIa was determined for gentamicin C1 and
gentamicin C2 (table 3). Gentamicin C2 had a lower activation energy and catalytic turnover
rate than gentamicin C1. The enthalpy, entropy and free energy of activation for both
gentamicin components were almost identical. When extrapolating the slopes on the
Arrhenius plot, gentamicin C1 and gentamicin C2 were modified equally as fast at -1°C (figure
22).

Figure 21: Arrhenius plots for AAC(3)-VIa with gentamicin C1 (black) and gentamicin C2
(orange). Gentmaicin components were modified equally as fast at -1°C.
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CHAPTER IV: FUTURE RESEARCH
It is well known that the addition of heat increases the rate of most reactions. Many
spontaneous reactions occur at extremely high temperatures that are not biologically feasible.
To better understand the release of enthalpy and rate enhancement produced by a catalyst,
spontaneous, uncatalyzed reaction rates need to be observed. Several complications arise
when measuring the spontaneous reactions catalyzed by aminoglycoside modifying enzymes.
For the APH family of enzymes, a coupled reaction measuring the disappearance of NADH is
used to measure the initial velocity rates. NADH becomes inactive at temperatures above
50°C. For the AAC family of enzymes, Acetyl coenzyme A is used as the acetyl donor in the
modification reaction. Acetyl CoA becomes unstable at temperatures higher than 37°C. In
order to measure the spontaneous reactions, variations of these reactions will need to be
developed. The difference in the rate enhancement produced by APH(3’)-IIIa and AAC(3)IIIb may provide a better understanding for their promiscuous nature while exhibiting very
different protein dynamics in the apo- and enzyme bound-form. Comparing AAC(3)-IIIb and
AAC(3)-VIa may also provide further insight to the selectivity of substrates between two
enzymes within the same family of aminoglycoside modifying enzymes that catalyze the
modification reaction by the same mechanism.
In addition to measuring the uncatalyzed reactions, future studies should consist of
determining the kinetic mechanism for AAC(3)-IIIb and AAC(3)-VIa, thermodynamic
properties with gentamicin components, and protein dynamics for AAC(3)-VIa. Viscosity
experiments should be conducted to determine the rate-limiting step for both of these
enzymes. Understanding the kinetic mechanism will provide further support on the stability
of the transition state. The thermodynamic parameters and protein dynamics when bound to
gentamicin C1 and C2 will provide further understanding for the potential hydrophobic
contributions that effect the activation energy.
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Figure 22: Temperature-dependent Michaelis-Menten curves for APH(3’)-IIIa with
kanamycin A. Initial velocity rates were measured by a coupled-enzyme assay (scheme 1A)
with various aminoglycoside concentrations at temperatures 37°C (A), 30°C (B), 25°C (C),
21°C (D), 15°C (E), 12°C (F). Steady-state kinetic parameters are shown in table 2.
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Figure 23: Temperature-dependent Michaelis-Menten curves for APH(3’)-IIIa with
paromomycin. Initial velocity rates were measured by a coupled-enzyme assay (scheme 1A)
with various aminoglycoside concentrations at temperatures 37°C (A), 36°C (B), 30°C (C and
D), 26°C (E), 25°C (F), 21°C (G), 20°C (H), 15°C (I), 10°C (J). Steady-state kinetic
parameters are shown in table 2.
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Figure 24: Temperature-dependent Michaelis-Menten curves for APH(3’)-IIIa with neomycin
B. Initial velocity rates were measured by a coupled-enzyme assay (scheme 1A) with various
aminoglycoside concentrations at temperatures 37°C (A), 30°C (B), 25°C (C), 18°C (D), 10°C
(E). Steady-state kinetic parameters are shown in table 2.
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Figure 25: Temperature-dependent Michaelis-Menten curves for APH(3’)-IIIa with
ribostamycin. Initial velocity rates were measured by a coupled-enzyme assay (scheme 1A)
with various aminoglycoside concentrations at temperatures 37°C (A), 30°C (B), 25°C (C),
21°C (D), 15°C (E), 12°C (F). Steady-state kinetic parameters are shown in table 2.
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Figure 26: Temperature-dependent Michaelis-Menten curves for AAC(3)-IIIb with
kanamycin A. Initial velocity rates were measured by a coupled reaction assay (scheme 1B)
with various aminoglycoside concentrations at temperatures 37°C (A), 30°C (B), 25°C (C),
19°C (D), 10°C (E). Steady-state kinetic parameters are shown in table 2.
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Figure 27: Temperature-dependent Michaelis-Menten curves for AAC(3)-IIIb with
gentamicin C1. Initial velocity rates were measured by a coupled reaction assay (scheme 1B)
with various aminoglycoside concentrations at temperatures 30°C (A), 25°C (B), 18°C (C),
12°C (D). Steady-state kinetic parameters are shown in table 2.

63

Figure 28: Temperature-dependent Michaelis-Menten curves for AAC(3)-IIIb with
gentamicin C2. Initial velocity rates were measured by a coupled reaction assay (scheme 1B)
with various aminoglycoside concentrations at temperatures 37°C (A), 30°C (B), 25°C (C),
18°C (D), 12°C (E). Steady-state kinetic parameters are shown in table 2.
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Figure 29: Temperature-dependent Michaelis-Menten curves for AAC(3)-IIIb with neomycin
B. Initial velocity rates were measured by a coupled reaction assay (scheme 1B) with various
aminoglycoside concentrations at temperatures 35°C (A), 30°C (B), 25°C (C), 20°C (D), 15°C
(E), 10°C (F). Steady-state kinetic parameters are shown in table 2.
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Figure 30: Temperature-dependent Michaelis-Menten curves for AAC(3)-IIIb with
paromomycin. Initial velocity rates were measured by a coupled reaction assay (scheme 1B)
with various aminoglycoside concentrations at temperatures 37°C (A), 30°C (B), 25°C (C),
18°C (D), 12°C (E). Steady-state kinetic parameters are shown in table 2.

66

Figure 31: Temperature-dependent Michaelis-Menten curves for AAC(3)-IIIb with
ribostamycin. Initial velocity rates were measured by a coupled reaction assay (scheme 1B)
with various aminoglycoside concentrations at temperatures 37°C (A), 30°C (B), 25°C (C),
18°C (D), 12°C (E). Steady-state kinetic parameters are shown in table 2.
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Figure 32: Temperature-dependent Michaelis-Menten curves for AAC(3)-VIa with
gentamicin C1. Initial velocity rates were measured by a coupled reaction assay (scheme 1B)
with various aminoglycoside concentrations at temperatures 30°C (A), 25°C (B), 18°C (C),
12°C (D). Steady-state kinetic parameters are shown in table 2.
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Figure 33: Temperature-dependent Michaelis-Menten curves for AAC(3)-VIa with
gentamicin C2. Initial velocity rates were measured by a coupled reaction assay (scheme 1B)
with various aminoglycoside concentrations at temperatures 37°C (A), 30°C (B), 25°C (C),
18°C (D), 12°C (E). Steady-state kinetic parameters are shown in table 2.
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